10:37 AM EDT, 08/06/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) unit Teva Pharmaceuticals said Wednesday that the US Food and Drug Administration has approved Ajovy for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years who weigh 45 kilograms or more.

Preventive treatment may help decrease the frequency of migraine attacks, the company said, adding Ajovy is given once a month and available for in-office or at home use.

Teva shares were rising 1.1% in recent trading.

Price: 15.89, Change: +0.17, Percent Change: +1.11